Allergan Tazoral regulatory update
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Allergan plans to conduct an FDA-requested clinical study of its oral tazarotene formulation Tazoral, as well as provide additional pharmacology and toxicology data, the firm says June 1 after receiving FDA's written response to a dispute resolution request for a September 2004 "not approvable" letter. The agency "outlined multiple potential options for improving oral tazarotene's risk-benefit profile," Allergan stated. "Based on…F DA's recommendations, Allergan plans to submit a development plan…a nd will provide details once an agreement has been reached." A July 2004 advisory committee deemed the company's risk management plan for the retinoid to be inadequate (1Pharmaceutical Approvals Monthly October 2004, In Brief)...
You may also be interested in...
Allergan Tazoral "not approvable"
Allergan will continue seeking a psoriasis indication for its oral tazarotene product Tazoral, the firm says following FDA's Sept. 24 "not approvable" letter. Among the "non-approvability issues" are the needs for a non-inferiority trial in severe psoriasis, an "acceptable" risk management plan and manufacturing deficiencies. Allergan "will work with the FDA to clarify" the request for a non-inferiority trial. The firm says it is "in the process of developing an appropriate risk mangement plan." The manufacturing issue "is either resolved or will be resolved shortly to the FDA's satisfaction," Allergan says. FDA's Dermatologic & Ophthalmic Drugs/Drug Safety & Risk Management advisory committees said that the Tazoral risk management plan was inadequate during a July 12 joint meeting...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.